Heska (HSKA) Completes Sale of Allergy Patent Portfolio
HSKA Hot Sheet
Dividend Yield: 3.3%
Heska Corporation (Nasdaq: HSKA) has completed the sale of its rights in a worldwide patent portfolio covering a number of major allergens and the genes that encode them to Allergopharma Joachim Ganzer KG for an undisclosed sum. As part of the agreement, Heska Corporation has exclusively licensed veterinary rights to the portfolio.
"This agreement provides us with additional capital as well as exclusive veterinary rights to the technology underlying this patent portfolio," said Robert Grieve, Heska's Chairman and CEO. "We intend to continue to focus our resources on the companion animal health market."
"This agreement provides us with additional capital as well as exclusive veterinary rights to the technology underlying this patent portfolio," said Robert Grieve, Heska's Chairman and CEO. "We intend to continue to focus our resources on the companion animal health market."
You May Also Be Interested In
- UPDATE: RR Donnelley (RRD) to Buy Edgar Online (EDGR) for $70.5M
- China Investment may nab $2B stake in Alibaba - Reuters
- Rhoen-Klinkum to recommend Fresenius (FMS) takeover offer -Bloomberg
Create E-mail Alert Related Categories
Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
